We read with great interest the recent study by Lindner et al. [1], which provides a comprehensive genetic landscape of stage II melanoma. We commend the authors for investigating a robust cohort of 193 therapy-naïve patients. Importantly, their rigorous multivariate analysis demonstrating the prognostic significance of the 11q23.1-3 (CBL) deletion in the overall cohort provides a compelling foundation for exploring this alteration as potential biomarker.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Xinger
Contact Xinger, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack